Vision loss is a major global health problem, affecting over a quarter of a billion people worldwide. Blindness and visual impairment can have a devastating impact on those people affected, including patients and their caregivers; potentially limiting social interaction and independence, impacting ability to work and leading to depression and anxiety.
At Roche, our pioneering clinical programmes focus on some of the main causes of blindness and visual impairment globally, where the unmet need is high – diseases of the retina. These include neovascular age-related macular degeneration (AMD), diabetic eye disease, and geographic atrophy, for which there are currently no or limited treatment options.
Leaders in innovation
Retinal diseases can be difficult to treat because the way they develop and progress varies from person to person. Our approach to innovation in ophthalmology centres on harnessing our in-depth understanding of the underlying disease biology, and combining this with new data and analytical sources such as real world data, machine learning, and advanced algorithms. This approach will potentially allow us to design and assess therapies that target new pathways, work in novel ways or are administered via long-acting delivery mechanisms.
Taken together, we believe we are ideally placed to deliver highly personalised and effective solutions to improve quality of vision and quality of life for people with retinal diseases.
Committed to the ophthalmology community
Our work in ophthalmology is driven by our commitment to make a real difference to people with vision loss and their caregivers, building on our legacy of pioneering breakthrough therapies for those who need them. We truly value our relationships and collaborations with researchers, clinicians and patient groups, allowing us, as a community, to advance science in ophthalmology and improve care for people with eye diseases.